Claude Science: Anthropic's Flagship AI for Life Sciences
Anthropic launched Claude Science as a flagship AI workbench for life sciences research on June 30. The product replaces Claude for Life Sciences, a set of plugins released in October 2025. Eric Kauderer-Abrams, the company's head of life sciences, has said life sciences represent the area with the greatest potential to serve humanity through AI.
Claude Science autonomously executes scientific research workflows from high-level instructions. It integrates tools and packages used in computational biology and drug development, produces auditable artifacts, and gives researchers flexible computing access. The platform is available to all paid Claude subscribers.
The launch pits Anthropic against Google DeepMind's Isomorphic Labs and Microsoft's Azure AI for Health in AI-driven drug discovery. Claude Science differentiates itself as a customizable general-purpose workbench rather than a narrow specialized tool.
Anthropic also announced it will use Claude Science for its own research into drugs for rare neglected diseases. The dual role as platform provider and drug developer could provide real-world validation but also raises questions about competing with customers.
The autonomous execution model reduces hands-on oversight, and the auditable artifact generation addresses traceability requirements in regulated environments. The platform's availability to all paid subscribers rather than only enterprise customers suggests Anthropic aims for broad adoption across academic labs, startups, and pharmaceutical companies.
Sources
Newsroom | Anthropic - Claude Science announcement
Photo by Brecht Corbeel on Unsplash
Related Articles
- Claude Managed Agents Debut as Anthropic Hits $800B
- Anthropic Debuts Claude Opus 4.8 on AWS to Power Agentic Coding and Enterprise Tasks
- Amazon Web Services Launches Native Claude Platform on AWS for Enterprise Developers
✔Human Verified
Researched and cross-referenced against primary sources by the Bytevyte editorial team.